Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
TCG Crossover Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
TCG Crossover Management

TCG Crossover Management

Operating

TCG X: A Palo Alto-based healthcare investment firm, advancing disruptive medicines and patient care.

Location
Palo Alto, CA, US
Founded
2020
Firm
Compare
Portfolio
Employees
Website

TCG Crossover Management is a science-driven investment firm focused on advancing disruptive medicines in the healthcare sector. Based in Palo Alto and New York City, the firm invests in both private and public companies, typically participating in Series A to Series E rounds and post-IPO equity investments.

The firm's portfolio includes notable companies such as Adarx Pharmaceuticals, Affinia Therapeutics, and Eikon Therapeutics. TCG Crossover supports exceptional entrepreneurs developing innovative treatment options, demonstrating a commitment to improving patient care through strategic investments in biotechnology and pharmaceutical companies.

TCG Crossover Management - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments18
Current Portfolio Count15
Total Portfolio Exits1

Top Investment Stages

Series B8 (44.4%)
Post Ipo Equity4 (22.2%)
Series A4 (22.2%)
Series C1 (5.6%)
Series E1 (5.6%)

Stage Mix

Series B 44%Post Ipo Equity 22%Series A 22%Series C 6%Series E 6%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Silence Therapeutics logo

Silence Therapeutics

Astria Therapeutics logo

Astria Therapeutics

Taysha Gene Therapies logo

Taysha Gene Therapies

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Upstream Bio logo

Upstream Bio

Alkeus Pharmaceuticals logo

Alkeus Pharmaceuticals

Carmot Therapeutics logo

Carmot Therapeutics

Aktis Oncology logo

Aktis Oncology

Plexium logo

Plexium

Arbor Biotechnologies logo

Arbor Biotechnologies

Alpine Immune Sciences logo

Alpine Immune Sciences

Obsidian Therapeutics logo

Obsidian Therapeutics

Synthekine logo

Synthekine

Eikon Therapeutics logo

Eikon Therapeutics

Affinia Therapeutics logo

Affinia Therapeutics

Entrada Therapeutics logo

Entrada Therapeutics

TCG Crossover Management - Similar Investment Firms

The Column Group logo

The Column Group

thecolumngroup.com

Crosspoint Capital Partners logo

Crosspoint Capital Partners

Atreides Management logo

Atreides Management

atreidesmgmt.com

Crosslink Capital logo

Crosslink Capital

TCJ Ventures logo

TCJ Ventures

tcjventures.com

Sequoia Capital Global Equities logo

Sequoia Capital Global Equities

sequoiacap.com

XSeed Capital logo

XSeed Capital

xseedcap.com

Intersect VC logo

Intersect VC

Endpoint Ventures logo

Endpoint Ventures

endpoint.vc

TGM Ventures logo

TGM Ventures

tgm.com

PFM Health Sciences logo

PFM Health Sciences

Project X logo

Project X

projectx.capital

Tectonic Capital logo

Tectonic Capital

tectonic.vc

Flagship Pioneering logo

Flagship Pioneering

Versant Ventures logo

Versant Ventures

TCG Crossover Management - Classification

Also Known As
  • TCG Crossover Management, LLC
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 5 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
  • 523910Miscellaneous Intermediation
SIC
  • 6000Depository Institutions
  • 6790Miscellaneous Investing
  • 6799Investors, Not Elsewhere Classified